BracheV, CochonL, DeniaudM, et al.Ulipristal acetate prevents ovulation more effectively than levonorgestrel: Analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception, 2013; 88(5):611–618.
2.
ShenJ, CheY, ShowellE, et al.Interventions for emergency contraception. Cochrane Database Syst Rev, 2017; 8(8):CD001324.
3.
GlasierA, CameronST, BlitheD, et al.Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception, 2011; 84(4):363–367.
4.
CheralaG, EdelmanA, DorflingerL, et al.The elusive minimum threshold concentration of levonorgestrel for contraceptive efficacy. Contraception, 2016; 94:104–108.
5.
PraditpanP, HamouieA, BasarabaCN, et al.Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. Contraception, 2017; 95: 464–469.
6.
EdelmanAB, CheralaG, BlueSW, et al.Impact of obesity on the pharmacokinetics of levonorgestrel- based emergency contraception: Single and double dosing. Contraception, 2016; 94:52–57.
7.
TurokDK, GeroA, SimmonsRG, et al.Levonorgestrel vs. copper intrauterine devices for emergency contraception. N Engl J Med, 2021; 384(4):335–344.
8.
OrtelTL, NeumannI, AgenoW, et al.American Society of Hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism. Blood Adv, 2020; 4(19):4693–4738.
9.
GialerakiA, ValsamiS, PittarasT, et al.Oral contraceptives and HRT risk of thrombosis. Clin Appl Thromb Hemost, 2018; 24(2):217–225.
10.
TepperNK, WhitemanMK, MarchbanksPA, et al.Progestin-only contraception and thromboembolism: A systematic review. Contraception, 201; 94(6):678–700.
11.
KuhnzW, HeunerA, HümpelM, et al.In vivo conversion of norethisterone and norethis- terone acetate to ethinyl estradiol in postmenopausal women. Contraception, 1997; 56:379–385.
12.
ChuMC, ZhangX, GentzscheinE, et al.Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J Clin Endocrinol Metab, 2007; 92:2205–2207.
13.
van Hylckama VliegA, HelmerhorstFM, RosendaalFR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol, 2010; 30(11):2297–2300.
14.
CurtisKM, TepperNK, JatlaouiTC, et al.U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep, 2016; 65(No. RR-3):1–104.
15.
HarmonQE, BairdDD. Use of depot medroxyprogesterone acetate and prevalent leiomyoma in young African American women. Hum Reprod, 2015; 30:1499–1504.
16.
WiseLA, PalmerJR, HarlowBL, et al.Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: A prospective study. Am J Epidemiol, 2004; 159(2):113–123.
17.
LumbiganonP, RugpaoS, Phandhu-fungS, et al.Protective effect of depot- medroxyprogesterone acetate on surgically treated uterine leiomyomas: A multicentre case-control study. BJOG, 1996; 103: 909–914.
18.
LawaniOL, AnomieOB, EzeonuPO. Ectopic pregnancy: A life-threatening gynecological emergency. Int J Womens Health, 2013; 5:515–521.
19.
MannLM, KreiselK, LlataE, et al.Trends in ectopic pregnancy diagnoses in United States emergency departments, 2006–2013. Matern Child Health J, 2020; 24(2):213–221.
CallahanR, YacobsonI, HalpernV, et al.Ectopic pregnancy with use of progestin-only injectables and contraceptive implants: A systematic review. Contraception, 2015; 92:514–522.
22.
GaffieldME, CulwellKR, LeeCR. The use of hormonal contraception among women taking anticonvulsant therapy. Contraception, 2011; 83:16–29.
23.
LazorwitzA, DavisA, SwartzM, et al.The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users. Contraception, 2017; 95:571–577.
24.
LangeJ, TealS, TocceK. Decreased efficacy of an etonogestrel implant in a woman on antiepileptic medications: A case report. J Med Case Rep, 2014; 8:43.
25.
MilneRL, AntoniouAC. Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers. Endocr Relat Cancer, 2016; 23(10):T69–T84.
26.
KuchenbaeckerKB, HopperJL, BarnesDR, et al.Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA, 2017; 317:2402–2416.
27.
KotsopoulosJ, LubinskiJ, GronwaldJ, et al.Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Int J Cancer, 2015; 137:1136–1146.
28.
HavrileskyLJ, MoormanPG, LoweryWJ, et al.Oral contraceptive pills as primary prevention for ovarian cancer: A systematic review and meta-analysis. Obstet Gynecol, 2013; 122:139–147.
29.
KumleM, WeiderpassE, BraatenT, et al.Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Br J Cancer, 2004; 90:1386–1391.
